Concepedia

Daniel L. Suzman

DL

Statistics

Publications

33

Citations

2.6K

H-Index

21

Active since

2003

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Sidney Kimmel Comprehensive Cancer Center

Johns Hopkins University

National Institute of Allergy and Infectious Diseases

Daniel L. Suzman is an author at United States Food and Drug Administration specializing in oncology, medicine, and prostate cancer.

ORCID

Publications per year

2003–2024

33

Publications

33

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal et al. · The Oncologist · 2016 · 478 citations · Full text

, , +12

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

V. Ellen Maher, Laura L. Fernandes, Chana Weinstock et al. · Journal of Clinical Oncology · 2019 · 346 citations

, , +17

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Jaleh Fallah, Sundeep Agrawal, Haley Gittleman et al. · Clinical Cancer Research · 2022 · 220 citations · Full text

, , +17

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy

Daniel L. Suzman, Sundeep Agrawal, Yang‐Min Ning et al. · The Oncologist · 2018 · 200 citations · Full text

, , +15

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang et al. · The Oncologist · 2020 · 182 citations · Full text

, , +14

1–5 of 33